We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+5.06%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$11.8B
AUM Growth
+$261M
Cap. Flow
+$368M
Cap. Flow %
3.12%
Top 10 Hldgs %
80.71%
Holding
127
New
5
Increased
21
Reduced
20
Closed
13

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$268M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$210M
3
AVXS
AveXis, Inc. Common Stock
AVXS
+$46.6M
4
HRTX icon
Heron Therapeutics
HRTX
+$44.6M
5
ACGN
Aceragen Inc
ACGN
+$41M

Top Sells

Rank Stock Value
1
ABLX
Ablynx NV
ABLX
+$98.3M
2
RXDX
Ignyta, Inc.
RXDX
+$37M
3
IMGN
Immunogen Inc
IMGN
+$16.4M
4
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$10.8M
5
ANAB icon
AnaptysBio
ANAB
+$10.2M

Sector Composition

Rank Sector Weight
1 Healthcare 93.85%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
76
DELISTED
Adamas Pharmaceuticals
ADMS
$4.13M 0.04%
172,630
– –
CRBP icon
77
Corbus Pharmaceuticals
CRBP
$165M
$4.03M 0.03%
22,024
– –
CMTA
78
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$3.79M 0.03%
250,000
– –
LUMO
79
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.68M 0.03%
56,364
-55,555
-50% -$3.94M
TRIL
80
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.95M 0.03%
409,323
– –
TTPH
81
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$2.87M 0.02%
46,750
– –
ARAV
82
DELISTED
Aravive, Inc. Common Stock
ARAV
$2.35M 0.02%
237,718
– –
JNCE
83
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$2.23M 0.02%
100,000
– –
NTRA icon
84
Natera
NTRA
$36.4B
$2.12M 0.02%
228,676
– –
TNXP icon
85
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
KRYS icon
86
Krystal Biotech
KRYS
$10.7B
$2.02M 0.02%
200,000
– –
OVID icon
87
Ovid Therapeutics
OVID
$427M
$1.75M 0.01%
247,733
-85,600
-26% -$693K
CLLS
88
Cellectis
CLLS
$288M
$1.58M 0.01%
50,000
– –
TRVN
89
DELISTED
Trevena, Inc.
TRVN
$1.56M 0.01%
1,520
– –
VIRX
90
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.51M 0.01%
15,905
-5,285
-25% -$906K
DVAX
91
DELISTED
Dynavax Technologies
DVAX
$1.49M 0.01%
75,000
– –
INFI
92
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.22M 0.01%
580,400
– –
MDWD icon
93
MediWound
MDWD
$184M
$1.18M 0.01%
32,286
– –
ADAP
94
DELISTED
Adaptimmune Therapeutics
ADAP
$1.12M 0.01%
100,000
– –
RNAC icon
95
Cartesian Therapeutics
RNAC
$218M
$955K 0.01%
3,125
-6,332
-67% -$1.8M
RARX
96
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$945K 0.01%
177,952
– –
ABUS icon
97
Arbutus Biopharma
ABUS
$847M
$903K 0.01%
180,582
– –
AIXC
98
AIxCrypto Holdings Inc
AIXC
$13.2M
$762K 0.01%
22
– –
TARA icon
99
Protara Therapeutics
TARA
$214M
$746K 0.01%
7,465
– –
AFMD
100
DELISTED
Affimed
AFMD
$740K 0.01%
40,000
– –
1 2 3
4
5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2018 Portfolio in Review

As of Q1 2018, Baker Bros. Advisors held 127 positions worth $11.8B, up 2.3% from $11.5B the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Baker Bros. Advisors deployed $368M of net new capital in Q1 2018, opening 5 new positions and adding to 21 existing holdings. Its largest new stake was VYNE Therapeutics: 194 shares worth $26.3M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Ablynx NV, an estimated $98.3M trimmed.

  • Baker Bros. Advisors's largest Q1 2018 buy was VYNE Therapeutics: 194 shares worth $26.3M.
  • Baker Bros. Advisors added most to BeOne Medicines Ltd in Q1 2018, an estimated $268M increase.
  • Baker Bros. Advisors's biggest Q1 2018 reduction was Ablynx NV, cutting an estimated $98.3M.
  • Baker Bros. Advisors fully exited Ignyta, Inc. in Q1 2018, selling an estimated $37M.
  • Baker Bros. Advisors's ten largest holdings make up 81% of its $11.8B portfolio in Q1 2018.
  • Baker Bros. Advisors opened 5 new positions and closed 13 in Q1 2018.
  • Baker Bros. Advisors's portfolio value rose 2.3% quarter-over-quarter to $11.8B.

Based on Baker Bros. Advisors's 13F filing for Q1 2018, filed 15 May 2018.